{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:42:37Z","timestamp":1790764957594,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40265-023-01918-0","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T12:01:50Z","timestamp":1689163310000},"page":"1207-1213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-9604","authenticated-orcid":false,"given":"Laurent","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"issue":"Suppl 1","key":"1918_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/liv.14862","volume":"41","author":"S Pol","year":"2021","unstructured":"Pol S, Lair-Mehiri L, Vallet-Pichard A. Is elimination of HCV realistic by 2030: France. Liver Int. 2021;41(Suppl 1):45\u20139.","journal-title":"Liver Int"},{"key":"1918_CR2","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"J-M Pawlotsky","year":"2020","unstructured":"Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series\u2606. J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol"},{"key":"1918_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. The Lancet. 2019;393:1453\u201364.","journal-title":"The Lancet"},{"key":"1918_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.4765","volume":"2","author":"EA McGlynn","year":"2019","unstructured":"McGlynn EA, Adams JL, Kramer J, Sahota AK, Silverberg MJ, Shenkman E, et al. Assessing the safety of direct-acting antiviral agents for hepatitis C. JAMA Netw Open. 2019;2: e194765.","journal-title":"JAMA Netw Open"},{"key":"1918_CR5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1056\/NEJM197104222841604","volume":"284","author":"AL Herbst","year":"1971","unstructured":"Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878\u201381.","journal-title":"N Engl J Med"},{"key":"1918_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jama.281.9.824","volume":"281","author":"T Brewer","year":"1999","unstructured":"Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824.","journal-title":"JAMA"},{"key":"1918_CR7","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMc1505967","volume":"373","author":"H Fontaine","year":"2015","unstructured":"Fontaine H, Lazarus A, Pol S, Pecriaux C, Bagate F, Sultanik P, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373:1886\u20138.","journal-title":"N Engl J Med"},{"key":"1918_CR8","unstructured":"FDA. Center for Drug Evaluation and Research. Application number: 204671Orig1s000. Pharmacology Review(s). [Internet]. 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204671Orig1s000PharmR.pdf"},{"key":"1918_CR9","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug [Internet]. FDA; 2015. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-serious-slowing-heart-rate-when-antiarrhythmic-drug"},{"key":"1918_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/pds.5576","volume":"32","author":"L Lam","year":"2023","unstructured":"Lam L, Fontaine H, Lapidus N, Dorival C, Bellet J, Larrey D, et al. Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers. Pharmacoepidemiol Drug Saf. 2023;32:486\u201395.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1918_CR11","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65:S149\u201367.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"1918_CR12","doi-asserted-by":"publisher","first-page":"e1017","DOI":"10.1097\/MEG.0000000000002173","volume":"33","author":"KN Hayes","year":"2021","unstructured":"Hayes KN, Burkard T, Weiler S, Tadrous M, Burden AM. Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase. Eur J Gastroenterol Hepatol. 2021;33:e1017\u201321.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1918_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamainternmed.2023.0554","volume":"183","author":"L Lam","year":"2023","unstructured":"Lam L, Carrat F. Immortal time and selection biases in study of direct-acting antiviral treatment and hepatitis c outcomes. JAMA Intern Med. 2023;183:624.","journal-title":"JAMA Intern Med"},{"key":"1918_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","volume":"183","author":"E Ogawa","year":"2023","unstructured":"Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, et al. Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C. JAMA Intern Med. 2023;183:97.","journal-title":"JAMA Intern Med"},{"key":"1918_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1053\/j.gastro.2015.09.031","volume":"149","author":"DJ Back","year":"2015","unstructured":"Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149:1315\u20137.","journal-title":"Gastroenterology"},{"key":"1918_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hep.27488","volume":"62","author":"T Ahmad","year":"2015","unstructured":"Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015;62:409\u201316.","journal-title":"Hepatology"},{"key":"1918_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/gutjnl-2017-313869","volume":"67","author":"A Laurain","year":"2018","unstructured":"Laurain A, Kramer L, Sultanik P, Vallet-Pichard A, Sogni P, Pol S. Mortality associated with the treatment of HCV with direct-acting antivirals. Gut. 2018;67:197\u20138.","journal-title":"Gut"},{"key":"1918_CR18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/s12879-018-3426-9","volume":"18","author":"M Mazzitelli","year":"2018","unstructured":"Mazzitelli M, Torti C, Sabatino J, D\u2019Ascoli GL, Costa C, Pisani V, et al. Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. BMC Infect Dis. 2018;18:518.","journal-title":"BMC Infect Dis"},{"key":"1918_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature02099","volume":"426","author":"D Lamarre","year":"2003","unstructured":"Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186\u20139.","journal-title":"Nature"},{"key":"1918_CR20","doi-asserted-by":"publisher","first-page":"791.e5","DOI":"10.1016\/j.cmi.2021.02.013","volume":"27","author":"A Touafchia","year":"2021","unstructured":"Touafchia A, Bagheri H, Carri\u00e9 D, Durrieu G, Sommet A, Chouchana L, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect. 2021;27:791.e5-791.e8.","journal-title":"Clin Microbiol Infect"},{"key":"1918_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01918-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:28:19Z","timestamp":1693214899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01918-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01918-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"22 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"FC reports grants from INSERM-ANRS; personal fees from Sanofi, outside the submitted work. SP has received consulting and lecturing fees from Janssen, Gilead, MSD, Abbvie, Biotest, Shinogui, Viiv, LFB, and grants from Bristol-Myers Squibb, Gilead, Roche and MSD without relation to this manuscript. AC has received research grants from ARS, RESICARD (research nurses), and Boehringer-Ingelheim; and consultant and lecture fees from Amgen, AstraZeneca, Bayer Pharma, BMS-Pfizer alliance, Boehringer-Ingelheim, Daiichi Sankyo, Novartis, and VIFOR. LL has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Due to the nature of this research based on the French administrative health care database, data that support the findings of this study are not available due to ethical and legal restrictions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The authors had permanent access to the SNDS (French decree no. 2021-848). All data were anonymized, and no informed consent was required. The study was approved by INSERM CepiDC and conducted in accordance with the Declaration of Helsinki and the French law on biomedical research. Ethics approval by an ethics committee or institutional review board was not required for this research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LL and FC had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: LL and FC. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: LL. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: LL and FC. All authors read and approved the final version of the submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency Statement"}}]}}